A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

Published:2015-11-04 Issue:S2 Volume:3 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Weber Jeffrey,Grob Jean-Jaques,Margolin Kim A,Ascierto Paolo A,Sznol Mario,Ott Patrick A,Lejeune Chantal,de Pril Veerle,Ruisi Mary M,Hodi F Stephen

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/2051-1426-3-S2-P166.pdf

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring Advancements and Challenges in Adjuvant Melanoma Treatment;EMJ Dermatology;2024-01-30

2. Uveal Melanoma: Adjuvant Therapy;Clinical Ophthalmic Oncology;2019

3. Bullous Pemphigoid–like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature;Journal of Immunotherapy;2018-04

4. Melanoma Immunotherapy;Early Phase Cancer Immunotherapy;2017-11-04

5. Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study;Annals of Surgical Oncology;2017-05-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP